:: Volume 22, Issue 3 (5-2018) ::
ibj 2018, 22(3): 140-141 Back to browse issues page
Streptokinase for Treatment of Thrombotic Disorders: The End? Or the End of the Beginning?
Farzin Roohvand *
Abstract:  
Thrombotic disorders, such as myocardial infarction, ischemic stroke, peripheral arterial disease, deep venous thrombosis, pulmonary embolism, or other embolic diseases that are responsible for worldwide mortality and morbidity, are manifestations of the formed thrombi by blood clots during a pathologic blood coagulation process. Once thrombi are formed, the only way to resolve the blood clot is treatment with specific thrombolytic agents, so called plasminogen activators (PAs), such as tissue-PAs (tPAs), urokinase, and streptokinase (SK). PAs convert the endogenous human plasminogen (HPG: the inactive proenzyme) to plasmin (HPM: the active enzyme), which cleaves the fibrin network of the blood clot, a process known as fibrinolysis (Fig. 1)...
Full-Text [PDF 641 kb]      
Type of Study: Study Break | Subject: Related Fields
Add your comments about this article
Your username or Email:

CAPTCHA code


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Roohvand F. Streptokinase for Treatment of Thrombotic Disorders: The End? Or the End of the Beginning?. ibj. 2018; 22 (3) :140-141
URL: http://ibj.pasteur.ac.ir/article-1-2256-en.html


Volume 22, Issue 3 (5-2018) Back to browse issues page
Persian site map - English site map - Created in 0.17 seconds with 37 queries by YEKTAWEB 3781